ArticleHereditas2026
MiR-642a-3p increases the risk of postmenopausal osteoporosis and fractures by targeting INO80.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostmenopausal osteoporosis (PMO), a metabolic bone disorder from estrogen deficiency, disrupts the balance between bone resorption and formation. Its severe consequence, osteoporotic fractures (OPF), significantly increases disability and mortality, severely impacting patients' quality of life. Elevated miR-642a-3p has been identified in both PMO and bone loss. This research aims to further explore the role of miR-642a-3p in predicting PMO development and OPF risk, along with its underlying mechanisms.
resultsThe research enrolled 127 PMO patients and 91 healthy volunteers (HV). And further subdivided the PMO group into osteoporotic fractures (n = 62) subgroup and without fractures (OPNF, n = 65) subgroup. The results indicate that miR-642a-3p was significantly upregulated in both the PMO and OPF groups. MiR-642a-3p demonstrated good predictive performance for PMO occurrence and OPF risk. High miR-642a-3p expression was identified as an independent risk factor for progression from PMO to OPF. Downregulation of miR-642a-3p not only stimulated osteoblast proliferation but also mitigated associated inflammation and oxidative stress. Furthermore, INO80 is targeted and regulated by miR-642a-3p.
conclusionMiR-642a-3p may have potential as a biomarker for future clinical prediction of PMO and OPF. Inhibition of miR-642a-3p promotes osteoblast proliferation, associated inflammation, and oxidative stress by upregulation of INO80 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.